Chapter 68 Infectious Diarrhea From Wilderness and Foreign Travel
Acute infectious diarrhea is one of the most common and significant medical problems in any population, second only to acute upper respiratory diseases. Worldwide, diarrheal diseases were reported to cause nearly 1 billion episodes of illness in 1996.182 The rates of illness among children in developing areas of the world range from 5 to 15 bouts per child per year, with diarrhea being the most important cause of morbidity and mortality in many regions. Readily available oral rehydration solutions prevent great numbers of dehydration-associated deaths related to acute diarrhea, especially in developing areas, but invasive bacterial enterocolitis (caused by Shigella species and Campylobacter spp.), persistent diarrhea (defined as illness lasting 14 days or longer), malnutrition, and increased susceptibility to other infections still cause significant morbidity and mortality.182
General Principles of Enteric Disease
Epidemiology
Outbreaks of infectious diarrhea in day care centers among non-toilet-trained toddlers are associated with low inoculum organisms, including Shigella, Cryptosporidium, Giardia and the viral pathogens. Hospitals, especially intensive care units and pediatric wards, institutions for mentally handicapped patients, and nursing homes are also locations with a high incidence of diarrheal diseases. Clostridium difficile is the most important definable pathogen in those settings.160 Salmonella species, rotavirus, and enteropathogenic Escherichia coli (EPEC) may on occasion cause nosocomial outbreaks.
Antimicrobial therapy is indicated for moderate to severe TD. When a specific bacterial or parasitic pathogen is identified (see later details), C. difficile infection (CDI) is frequently related to recent use of an antimicrobial agent (or cytotoxic agent) in debilitated hospitalized patients with a high rate of CDI recurrence.75
In developing areas of the world, children under 5 years of age have the highest morbidity of diarrhea, and infants under 1 year of age experience the highest mortality rates.40 The enteropathogens more common in infectious diarrhea during childhood are rotavirus, enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enteroaggregative E. coli (EAEC), Campylobacter spp., and Giardia. Residents in industrialized countries, such as the United States, have only one to two bouts of diarrhea per person per year, with no difference between age groups. Complications, including death, are more common in elderly persons.122
Food intoxication, caused by ingestion of preformed toxins from Staphylococcus aureus or Bacillus cereus, typically has a short incubation period (2 to 7 hours) and causes common source outbreaks involving multiple persons.41 Infection and diarrhea caused by a living enteropathogen must first traverse the stomach and infect the small bowel or colon, explaining a longer incubation period of 14 or more hours, usually more than 1 day.
Most cases of acute diarrhea are caused by infectious microorganisms, including bacteria, viruses, and protozoa. Fungal agents have been reported rarely. Table 68-1 lists the etiologic agents often associated with travel to developing tropical areas or with wilderness travel in an industrialized region. Foodborne illness may consist of food “poisoning” or food “infection.” In food poisoning, an intoxication results when toxins produced by bacteria are found in food in sufficient concentrations to produce symptoms. A rare cause of food poisoning that results in paralysis is botulism, caused when the neurotoxin of Clostridium botulinum is ingested. Other foodborne pathogens are viruses, including rotavirus and small round viruses (noroviruses, astrovirus, etc.), and intestinal protozoal agents, including Giardia, Entamoeba histolytica, and Cryptosporidium.
Agents | Travel to Developing Tropical Regions | Wilderness Travel in Industrialized Regions |
---|---|---|
Bacteria | ||
Enterotoxigenic Escherichia coli | Yes | Rarely |
Enteroinvasive E. coli | Rarely | Rarely |
Enteroaggregative E. coli | Yes | Rarely |
Salmonella spp. | Yes | Yes |
Shigella spp. | Yes | Yes |
Campylobacter spp. | Yes | Yes |
Vibrio cholerae | Limited | Not currently |
Yersinia enterocolitica | Rare | Limited |
Aeromonas spp. | Yes | Yes |
Plesiomonas shigelloides | Yes | Rarely |
Viruses | ||
Norovirus | Yes | Yes |
Rotavirus | Yes | Rarely |
Hepatitis A | Yes | Yes |
Protozoa | ||
Giardia lamblia | Yes | Yes |
Entamoeba histolytica | Yes | Rarely |
Cryptosporidium parvum | Yes | Yes |
Isospora belli | Limited | Rarely |
Cyclospora cayetanensis | Limited | Rarely |
Microsporidia | Limited | Rarely |
Balantidium coli | Limited | Rarely |
Sarcocystis | Limited | Rarely |
Blastocystis hominis | Limited | Rarely |
Pathophysiology
Three intestinal mechanisms lead to acute diarrhea. The most common pathophysiologic mechanism in acute infectious diarrhea is alteration of fluid and electrolyte movement from the serosal to the mucosal surface of the gut (secretory diarrhea). This alteration may occur as a result of cyclic nucleotide stimulation (as a second messenger) or by an inflammatory process that is associated with release of proinflammatory cytokines. The second mechanism is malabsorption or presence of nonabsorbable substances in the lumen of the bowel, including lactase deficiency and AIDS-associated malabsorption. The third mechanism of diarrhea is altered intestinal motility. Secretory mechanisms best explain acute infectious diarrhea, while malabsorption and altered motility are more important in chronic forms of diarrhea, such as tropical and nontropical sprue, Whipple’s disease, intestinal scleroderma, irritable bowel syndrome and inflammatory bowel disease. Table 68-2 shows the virulence factors of the most important enteric pathogens related to infectious diarrhea.
Pathogen | Virulence Properties |
---|---|
Vibrio cholerae | Heat-labile enterotoxin |
Vibrio parahemolyticus | Invasiveness (?), enterotoxin, hemolytic toxin |
Enterotoxigenic Escherichia coli | Heat-stable and heat-labile enterotoxins, colonization factor antigens |
Enteroinvasive E. coli | Shigella-like invasiveness |
Enteroaggregative E. coli | Enteroadherence |
Salmonella spp. | Cholera-like toxin, invasiveness |
Shigella spp. | Shiga-like toxin, invasiveness |
Campylobacter jejuni | Cholera-like toxin, invasiveness |
Aeromonas spp. | Hemolysin, cytotoxin, enterotoxin |
Yersinia enterocolitica | Heat-stable enterotoxiin, invasiveness |
Clostridium difficile | Toxins A and B |
Clostridium perfringens | Preformed toxin |
Bacillus cereus | Preformed toxin |
Staphylococcus aureus | Preformed toxin |
In secretory diarrhea, the unformed stools are usually of large volume and small in number (characteristically less than six bowel movements per day). Stools do not contain blood and fever is unusual. Examples of pathogens in this group are Vibrio cholerae, ETEC, preformed enterotoxins, noroviruses, rotavirus, Giardia, and Cryptosporidium. Dehydration is the major complication, especially in the extremes of age. Without adequate therapy, secretory diarrhea can be followed by renal insufficiency. Invasive pathogens involving the distal ileum and colon damage the mucosa and elicit an inflammatory response that is associated with secretory diarrhea and colitis. In this form of colitis, stools are typically liquid, small-volume, and may contain blood and many leukocytes. The common microorganisms in this group are Shigella, Salmonella, EIEC, Shiga-toxin producing E. coli (STEC), Yersinia enterocolitica, Campylobacter spp., Aeromonas, Vibrio parahaemolyticus, and E. histolytica. Complications include dehydration and systemic involvement, especially in children with malnutrition.151
Traveler’s Diarrhea
Traveler’s diarrhea is the most important travel-related illness in terms of frequency and economic impact. Point of origin, destination, and host factors are the main risk determinants.42 International travel is more often associated with enteric infection and diarrhea, particularly when the destination is a developing tropical region, although the same infections can be contracted domestically. The 2% to 4% rate of diarrhea for people who take short-term trips to low-endemic areas (e.g., United States, Canada, Northwestern Europe, Australia, Japan) may be related to more frequent consumption of food in public restaurants, increased intake of alcohol, or stress. This rate of diarrhea increases to about 10% for travelers from these low-endemic areas to northern Mediterranean areas, China, Russia, or some Caribbean islands. This incidence increases as high as 40% to 50% for short-term travelers from low-risk countries to high-risk countries (developing tropical and subtropical regions of Latin America, Southeast Asia, or Africa). More than 100 million persons travel each year from industrialized countries to high-risk areas, resulting in more than 30 million travelers with diarrhea.42 Multiple episodes of diarrhea may occur on the same trip. Attack rates remain high for the first 4 weeks in a country of risk,54 then decrease, but not to the levels of local inhabitants. Immunity to ETEC infection, either asymptomatic or symptomatic, occurs after repeated or chronic exposure, which supports the feasibility of developing a vaccine.72
Although any waterborne or foodborne enteropathogen can cause TD, bacteria are the most common etiologic agents among persons traveling to high-risk areas. The bacterial flora of the bowel changes rapidly after arrival in a country with high rates of TD. At least 15% of travelers remain asymptomatic despite the occurrence of infection by pathogenic organisms, including ETEC and Shigella.155
Definition
TD refers to an illness contracted while traveling, although in 15% of sufferers symptoms first become ill after returning home. Most clinical studies define TD as passage of three or more unformed stools in a 24-hour period in association with one or more enteric symptoms, such as abdominal cramps, fever, fecal urgency, tenesmus, bloody–mucoid stools, nausea, and vomiting.45
Etiology
Because the incidence of TD reflects in part the extent of environmental contamination with feces, the etiologic agents are pathogens causing illness in local children. A list of etiologic agents important in TD is provided in Table 68-3). Twenty years ago, specific pathogens were found in only 20% of cases. Currently, etiologic agents can be identified in up to 80% of TD episodes.103 In most studies, however, causative pathogens are not identified in 20% to 40% of cases. In most of these cases, antimicrobial therapy shortens illness, suggesting that this subset of diarrhea is caused by undetected bacterial pathogens.53 Overall, the major etiologic agents and their frequency of isolation are remarkably similar worldwide.
Agent | Frequency (%) | Distribution |
---|---|---|
Bacteria | 50-80 | |
Enterotoxigenic Escherichia coli | 5-50 | Developing countries, tropical areas, infants, travelers |
Enteroaggregative E. coli | 5-30 | Infants, worldwide |
Salmonella spp. | 1-15 | Worldwide |
Shigella spp. | 1-15 | Worldwide |
Campylobacter jejuni | 1-30 | Worldwide |
Aeromonas spp. | 0-10 | Worldwide, especially Thailand, Australia, Canada |
Plesiomonas shigelloides | 0-5 | Worldwide |
Other | 0-5 | |
Viruses | 0-20 | |
Rotavirus | 0-20 | Worldwide, children 6-24 mo |
Norovirus | 1-20 | Worldwide, cruise ships |
Protozoa | 1-5 | |
Giardia lamblia | 0-5 | Worldwide, zoonosis, alpine areas |
Entamoeba hystolitica | 0-5 | Developing and tropical countries, especially Mexico, India, western and South Africa, parts of South America |
Cryptosporidium parvum | 0-5 | Worldwide, including cooler developed countries |
Unknown | 10-40 |
For details on published studies see reference 177.
ETEC is the most common cause of TD worldwide,177 accounting for about one-third to one-half of cases. Since the last edition of this book, EAEC has been identified as the second most common bacterial cause of TD, causing up to 30% of TD cases in some areas of the world.3 One study has shown that the source of both types of E. coli is food. Viable ETEC and EAEC were found in hot sauces served on the table in popular restaurants in Guadalajara, Mexico.4 Shigella and Campylobacter species cause around 20% of illness. Other causes of TD include Salmonella (4% to 5% of cases), Vibrio, Aeromonas, Plesiomonas, viruses (10%), and parasites.177 Specific pathogens may predominate at a particular time or location.
Clinical Syndromes
Table 68-4 outlines the major syndromes in patients with enteric infection. The typical clinical syndrome experienced by travelers with diarrhea secondary to the major infectious causes (e.g., ETEC) begins abruptly with abdominal cramping and watery diarrhea. Most cases are mild, consisting of passage of one to two unformed stools per day associated with symptoms that are tolerable and do not interfere with normal activities. Approximately 30% of affected persons experience moderately severe illness, with three to five unformed stools per day and distressing symptoms that force a change in activities or itinerary. Only 1% to 3% of persons with TD occurring in Latin America or Africa experience febrile dysenteric illness,64,129 whereas approximately 9% of travelers with diarrhea acquired in Asia (Indian subcontinent) develop this more serious form of illness.187 TD may lead to a chronic illness43 and postinfectious irritable bowel syndrome (PI-IBS).147,190 TD should be considered a self-limited nonfatal condition. An illness associated with vomiting without important diarrhea is commonly seen in travelers and is characteristically due to noroviruses.6,113 Symptoms lasting more than 1 to 2 weeks suggest a protozoan etiology such as Giardia, E. histolytica, Cryptosporidium or other parasite.43
Syndrome | Agent |
---|---|
Acute watery diarrhea | Any agent, especially with toxin-mediated diseases (e.g., enterotoxogenic Escherichia coli, Vibrio cholerae) |
Febrile dysentery | Shigella, Campylobacter jejuni, Salmonella, Enteroinvasive E. coli, Aeromonas spp., Vibrio spp., Yersinia enterocolitica, Entamoeba histolytica, inflammatory bowel disease |
Vomiting (predominant symptom) | Viral agents, particularly noroviruses, preformed toxins of S. aureus or B. cereus |
Persistent diarrhea (>14 days) | Protozoa, small bowel bacterial overgrowth, inflammatory or invasive enteropathogens (Shigella, enteroaggregative E. coli) |
Chronic diarrhea (>30 days) | Small bowel injury, inflammatory bowel disease, irritable bowel syndrome (postinfectious), Brainerd diarrhea |
Persistent and Chronic Diarrhea
Diarrhea may persist after the traveler returns home. Up to 3% of persons with TD in high-risk areas will develop persistent diarrhea.43 Persistent diarrhea is defined as illness lasting 14 days or longer, whereas diarrhea is considered chronic when the illness has lasted 30 days or longer. The etiology of persistent or chronic diarrhea often differs from that of acute diarrhea. Important causes of persistent diarrhea include (1) protozoal parasitic agents (Giardia, Cryptosporidium, Cyclospora, and E. histolytica), (2) bacterial infection (Salmonella, Shigella, Campylobacter, and Y. enterocolitica), (3) lactase deficiency induced by a small bowel pathogen (Giardia, rotavirus, or norovirus), and (4) a small bowel bacterial overgrowth syndrome secondary to small bowel motility inhibition (as a result of enteric infection) or secondary to antimicrobial use. Occasionally, other parasitic enteric infections can cause more persistent illness. These include Strongyloides stercoralis, Trichuris trichiura, and severe infection by Necator americanus or Ancylostoma duodenale. In rare cases, more protracted diarrhea may be a prominent symptom in persons with schistosomiasis, Plasmodium falciparum malaria, leishmaniasis, or African trypanosomiasis.
When chronic diarrhea follows a bout of TD, a pathogen is not identified and the patient fails to respond to empiric antimicrobial therapy, PI-IBS, or activation of an underlying condition such as inflammatory bowel disease or celiac or tropical sprue should be considered. Even with eradication of microbial pathogens with antimicrobial therapy, bowel habits may not return to normal for several weeks. This represents slow repair of the damage to the intestinal mucosa. Small bowel bacterial overgrowth has been identified in patients with persistent diarrhea after a bout of TD. Finally, there first occurred in the 1980s an idiopathic form of chronic diarrhea called Brainerd diarrhea after the name of the city in Minnesota where the first outbreak was identified.150 The known vehicles of transmission of Brainerd diarrhea are raw (unpasteurized) milk150 and untreated water, such as well water.152 There is no diagnostic test or therapy, and the diagnosis is suspected based on the epidemiologic history (exposure to unpasteurized milk or untreated water just before onset of illness). Although the average duration of Brainerd diarrhea is 2 years, persons with this condition invariably become totally well.
Laboratory Tests and Procedures
Several laboratory tests are useful in evaluating patients with diarrheal disease (Table 68-5). In clinical practice, laboratory testing is reserved for illness continuing after the patient returns home or when empiric treatment is unsuccessful. Persons with milder forms of diarrhea usually need only clinical evaluation; etiologic assessment is unnecessary. Laboratory tests are reserved for persons with moderate to severe diarrhea and those with persistent illness.
Laboratory Test | Indication | Diagnosis/Agent |
---|---|---|
Fecal leukocytes or fecal lactoferrin | Moderate to severe cases | Diffuse colonic inflammation, invasive bacterial enteropathogen |
Stool culture | Moderate to severe diarrhea, fever, persistent diarrhea, fecal leukocytes or lactoferrin (+), male homosexual | Any bacterial enteric pathogen |
Blood culture | Enteric fever, sepsis | Salmonella, less likely Campylobacter, Shigella, Yersinia |
Parasite examination | Persistent diarrhea, travel to specific areas, day-care centers, male homosexuals | Any protozoan parasite |
Parasite enzyme immunoassay | Persistent diarrhea, travel to specific areas, day-care centers, male homosexuals | Giardia, Entamoeba histolytica, Cryptosporidium |
Amebic serology | Persistent diarrhea, liver abscess | Entamoeba histolytica |
Rotavirus antigen | Hospitalized infants (<3 years old). | Rotavirus |
Clostridium difficile toxin by EIA or PCR | Antibiotic associated diarrhea, especially occurring in the hospital | C. difficile |
EIA, Enzyme immunoassay; PCR, polymerase chain reaction
The presence of fecal leukocytes is a reliable indicator of diffuse colonic inflammation. For moderate to severe illness, this is the most rapid, useful test and the ideal screening procedure. A large number of polymorphonuclear leukocytes (PMNs) per high-power field using dilute methylene blue stain or trichrome stain (which also helps with identification of parasites) can be helpful in making an etiologic diagnosis (Figure 68-1) of Shigella, Salmonella, or Campylobacter spp.88 Other organisms and conditions that may lead to presence of fecal leukocytes in the stools are C. difficile, Aeromonas, Y. enterocolitica, V. parahaemolyticus, EIEC, idiopathic ulcerative colitis, and allergic colitis.
Lactoferrin is found in granules of neutrophils and can be identified in fecal samples by commercial immunoassay method (Leukotest, TechLab). This test does not require a freshly collected stool sample or an experienced technician, and is more sensitive than is microscopic examination of fecal leukocytes.21
Patients with persistent TD should be studied for presence of parasitic infection. Immunologic techniques to detect antigens of protozoan parasites are more efficient than are stool examinations for ova and parasites and are in common use for parasites that inhabit the duodenum (e.g., Giardia, Cryptosporidium, E. histolytica, Microsporidia).86,128 At times, intestinal parasites are better detected using a sample from duodenal aspiration or intestinal biopsy.86,128
Treatment
Treatment with intravenous (IV) fluids is indicated for
Symptomatic Therapy
Symptomatic medications are useful for treatment of milder forms of diarrhea, because they decrease symptoms and allow patients to return more quickly to normal activities. Lactobacillus preparations and yogurt are safe, but evidence is insufficient to establish their value in the therapy of TD. Adsorbent agents bind nonspecifically to water and other intraluminal material and make stools more formed. They have limited value in the treatment of acute diarrhea. The most useful drug for symptomatic therapy is the antimotility drug loperamide. In addition to slowing intestinal motility, these drugs alter water and electrolyte transport, probably affecting both secretion and absorption. Compared with placebo, antimotility drugs reduce the number of stools passed and the duration of illness by about 80%.46,51 The usual dose of loperamide is 4 mg initially. If diarrhea continues, the drug can be given in additional doses of 2 mg after each unformed stool, not to exceed 8 mg/day. Loperamide is not given for more than 2 days. Diphenoxylate with atropine is less expensive than loperamide, but has greater central opiate effects, a danger in case of accidental overdose by a child, and more side effects without antidiarrheal benefits because of the atropine, which is added only to prevent drug overdose. Tincture of opium or paregoric opium preparations are rapidly and equally effective and offer modest relief of symptoms. A major problem with this class of drugs is postdiarrhea constipation, so we recommend that only the loading dose be employed in most cases of diarrhea.
Antimotility drugs should never be used alone in patients who have dysenteric or febrile diarrhea, because inhibition of gut motility may facilitate intestinal infection by invasive bacterial enteropathogens.55 However, this theoretic deleterious effect does not appear to be an issue when loperamide is used concurrently with an effective antimicrobial agent.62,63,193 Antimotility drugs should not be given to children younger than 3 years of age.
Because increased secretion of water and electrolytes is the major physiologic derangement in acute watery diarrhea, therapy aimed at this effect is appealing. Although aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs) inhibit secretion,159 their safety is a concern because of gastric mucosal toxicity. The salicylate moiety of bismuth subsalicylate reduces the number of stools passed and duration of diarrhea by about 50%, altering secretion in the intestine. Bismuth subsalicylate also has antimicrobial and antiinflammatory properties. New compounds are being developed that have antisecretory properties without motility effects.37,50 Table 68-6 summarizes the recommended dosages of available symptomatic treatments.
Agent | Therapeutic Dose |
---|---|
Attapulgite | 3 g initially, then 3 g after each loose stool or every 2 hr (not to exceed 9 g/day); should be safe during pregnancy and childhood. (available in 600-mg tablets or liquid 600 mg/tsp) |
Loperamide | 4 mg initially; this is usually sufficient. If nonresponsive, can give 2 mg (one capsule) after each loose stool not to exceed 8 mg (four capsules)/day; do not use in dysenteric or febrile diarrhea. |
Bismuth subsalicylate | 30 mL or two 262-mg tablets every 30 min for eight doses; may repeat on day 2 |
Probiotics | Dose according to package, because products and formulations vary. Daily dose may make diarrhea less severe and shorten its duration; consider in postinfectious or postantibiotic diarrhea. |
Antimicrobial Therapy
Although most enteric infections do not require antibiotics, empiric antimicrobial therapy is indicated in acute TD and febrile, dysenteric illness, because of the importance of Shigella and Campylobacter as etiologic agents of this syndrome. Travelers with acute diarrhea and mild symptomatology usually do not need empiric antimicrobial therapy and can be treated with oral fluids and saltine crackers. Travelers with acute diarrhea and moderate symptoms, serious enough to change an itinerary, should be treated with antimicrobial empiric therapy or symptomatic therapy with loperamide or bismuth subsalicylate. Finally, travelers with more severe symptoms with any degree of incapacitation, or with dysentery, should be treated with empiric antimicrobial therapy, immediately after the first passage of the first unformed stool (Table 68-7).45 Loperamide can be given with the antibacterial drug for faster clinical response.57 Therapy for specific infections is discussed in the corresponding sections (Table 68-8).
Clinical Manifestations | Recommendations* |
---|---|
Watery diarrhea with mild symptoms (no change in itinerary) | Oral fluids and symptomatic therapy (can give antibiotics† or loperamide) |
Watery diarrhea with moderate symptoms (change in itinerary but able to function) | Symptomatic treatment with loperamide and antibiotics† after passage of first unformed stool |
Watery diarrhea with severe symptoms (incapacitating) | Antibiotic† after passage of first unformed stool |
Dysentery or fever | Azithromycin, 1000 mg in single dose; loperamide is not recommended |
Persistent diarrhea (>14 days) | Parasite examination and stool culture; consider gastrointestinal evaluation |
Vomiting, minimal diarrhea | Oral fluids and consider using bismuth subsalicylate |
Diarrhea in pregnant women | Fluids and electrolytes; if severely ill, treat with azithromycin 500 mg once a day for 3 days. |
* Treatment should be self initiated during travel without evaluation.
† Antibiotic options include: norfloxacin 400 mg twice a day for 1-3 days, ciprofloxacin 500 mg twice a day for 1-3 days, ofloxacin 300 mg twice a day for 1-3 days, or levofloxacin 500 mg once a day for 1-3 days; or rifaximin 200 mg three times a day for 3 days; or azithromycin 1000 mg in a single dose.
Diagnosis | Recommendation |
---|---|
Enterotoxigenic and enteroaggregative Escherichia coli diarrhea | Rifaximin 200 mg three times a day for 3 days; or ciprofloxacin 500 mg twice a day for 1-3 days; or norfloxacin 400 mg twice a day for 1 to 3 days; or levofloxacin 500 mg once a day for 1-3 days; or azithromycin 1000-mg single dose |
Cholera | Ciprofloxacin 1000-mg single dose; norfloxacin 400 mg twice a day or levofloxacin 500 mg once a day for 3 days; or doxycycline 300-mg single dose |
Systemic salmonellosis (typhoid fever or bacteremic infection) | Norfloxacin 400 mg twice a day for 5 days, or ciprofloxacin 500 mg twice a day for 5-7 days, or levofloxacin 500 mg once a day for 7-10 days |
Salmonellosis (intestinal nontyphoid salmonellosis without systemic infection) | Antimicrobial therapy controversial if systemically ill (high fever and toxicity) or in a high risk group: sickle cell anemia, age <3 mo or >64 yr, on corticosteroids, undergoing dialysis, those with inflammatory bowel disease (if decision to treat, use regimen like systemic salmonellosis above) |
Shigellosis | Norfloxacin 400 mg twice a day for 3 days, or ciprofloxacin 500 mg twice a day for 3 days, or levofloxacin 500 mg twice a day for 3 days |
Campylobacteriosis | Erythromycin 500 mg four times a day for 5 days; azithromycin 500 mg once a day for 3 days or 1000 mg in single dose |
Fluoroquinolones, azithromycin, and the rifaximin have adequate activity against most of the bacterial enteric pathogens to be considered useful for empiric therapy of TD.47 Ciprofloxacin is often the least expensive drug known to be effective. Problems196,201 with this drug are ineffectiveness for the common fluoroquinolone-resistant Campylobacter strains,196 depletion of gut flora,106 predisposing to CDI,142 and damage to articular cartilage.132
Azithromycin has been found to be a good alternative for treatment of acute TD. It is given in a dose of 1 g in a single dose for TD.196 Its main use is treatment of dysenteric and febrile TD. Azithromycin has the advantage of being useful and approved for pediatric TD (5 mg/kg/day for 3 days). Rifaximin (200 mg three times a day) was approved in 2004 by the U.S. Food and Drug Administration (FDA) for the treatment of TD caused by noninvasive E. coli in patients ≥12 years of age. Rifaximin is as effective as ciprofloxacin against noninvasive bacterial causes of TD.58
Travelers to high-risk regions should carry with them an antibacterial drug for treatment of bacterial diarrhea.47 A symptomatic drug, such as loperamide, may also be included for immediate relief of symptoms. If both drugs are employed in acute TD, persons should be instructed to take loperamide only if they have no fever and are not passing grossly bloody stools. The duration of antimicrobials needed in TD appears to be short for the absorbed drugs, fluoroquinolones or azithromycin. For rifaximin therapy, a full 3 days of treatment should be undertaken.
Prevention and Prophylaxis
Care in Food and Beverages Consumed During Travel
Food and water transmit the pathogens that cause infectious diarrhea and TD.4,195,206 When diarrhea occurs, however, the exact source cannot be determined. Being careful about what is eaten is recommended and may be helpful in reducing the occurrence of illness,115 but dietary habits usually cannot be rigidly controlled.179 Food in developing countries is often contaminated with fecal coliforms and enteropathogens.206 V. cholerae remains viable for 1 to 3 weeks in food,68 and Salmonella can survive 2 to 14 days in water or in the environment in a desiccated state.
Risk of illness is lowest when most of the meals are self-prepared and eaten in a private home, intermediate when food is consumed at public restaurants, and highest when food is obtained from street vendors.16 The following standard dietary recommendations for prevention are based more on known potential vehicles for transmission of illness than on strong evidence.
Chemoprophylaxis
Chemoprophylaxis with antibiotics was shown in the 1950s and 1960s to effectively prevent TD among international travelers.111 This was the first evidence that bacterial pathogens were the most important causes of TD. Preventive antibiotics are generally recommended to be used for trips of 2 weeks or less and will require a prescription from a physician (Table 68-9). Because of safety and efficacy, rifaximin is the optimal drug when prophylaxis is employed: the dose is one 200 mg tablet twice a day with major daily meals for trips up to 2 weeks in length. Another effective dosage formulation of rifaximin is a 550 mg tablet taken once for breakfast each day of the trip to high-risk regions. The medication should be started the day of arrival to a high-risk region and can be stopped once leaving the area. Most wilderness travelers taking their own food or preparing their own food are not at high enough risk for TD to justify chemoprophylaxis with antibiotics.